Anemia Clinical Trial
Official title:
Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants at Birth and Three Months of Age
In developing countries up to 50% of children become anemic by 12 months of age(1. Iron
deficiency anemia is a major risk factor for neonatal and infantile mortality and morbidity
in Pakistan. It has detrimental effects on neurodevelopment of infants and may be
irreversible even after iron therapy(2). Type of cost effective interventions during
perinatal period for prevention of anemia in later infancy is limited. Delayed cord clamping
has a beneficial effect on prevention of anemia in later infancy because of increased iron
stores at birth(3. However there are controversies in incorporating delayed cord clamping
practice in the management of third stage of labour globally(4) Paucity of national
guidelines and lack of substantial data in Pakistan on this topic strongly necessitates such
study trials. This study may contribute to develop a protocol on the timing of cord clamping
which will be cost effective in prevention of iron deficiency anemia in the investigators
infantile population.
The investigators will conduct a randomized controlled trial and the investigators
hypothesis is that delayed cord clamping will result in higher hemoglobin (Hb), hematocrit
(Hct) and ferritin at third month as compared to early cord clamping.
OBJECTIVES:
A- Primary:
1. To study the effect of timing of umbilical cord clamping on hemoglobin (Hb), Hematocrit
(Hct) at birth, 48 hours and Hb, Hct and ferritin at three months of age.
2. To study the effect of timing of umbilical cord clamping on short term clinical profile
of neonates like jaundice, respiratory distress, anemia, polycythemia etc. during fist
24 to 48 hours of life.
B- Secondary:
To assess whether delayed cord clamping is associated with undesirable effects on mothers
followed till 48 hours postpartum.
Delayed umbilical cord clamping (DCC) results in approximately 30-40 ml additional placental
blood volume transfusion to the neonate and 30-35 mg increase in iron stores at birth(5).The
neonatal benefits include higher hematocrit (Hct), higher red blood cells flow to vital
organs, better cardiopulmonary adaptation, additional iron stores and less anemia in later
infancy(6).It is evident from different studies that no adverse effects of DCC have been
noticed in mothers as well as in their neonates(7). The beneficial effect of delayed cord
clamping is not only observed in term infants but it has a positive impact on preterm and
small for gestational age (SGA) infants too. The requirement of packed cell transfusion in
first six months has significantly reduced as noticed from different studies(8).It is also
associated with lower risk of intraventricular hemorrhage and late onset sepsis in preterm
infants(9).
The practice of early cord clamping (ECC) is commonly following in our maternity units. It
is believed that it reduces the risk of post partum haemorrhage (PPH) and duration of third
stage of labour. But at the same time it does not provide any benefit to the
neonate(4).Conversely it increases the possibility of fetomaternal transfusion, hypovolemic
damage, neonatal anemia, respiratory distress syndrome and type 2 diabetes in later
life(5).The risk of iso immunization in rhesus negative mothers are also increased with
ECC(10).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |